RotationRx · Drugs · Scores · Protocols · Diagnoses · Specialties

← Drug Reference

Medroxyprogesterone

Prevention of pregnancy

Boxed warning

  • WARNING: LOSS OF BONE MINERAL DENSITY • Women who use Depo-Provera Contraceptive Injection (Depo-Provera CI) may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible [see Warnings and Precautions (5.1) ] . • It is unknown if use of Depo-Provera CI during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life [see Warnings and Precautions ... (see full label)

Indications

  • Prevention of pregnancy

Adult dosing

  • prevention of pregnancy: dose: 150; unit: mg; route: IM; interval: every 3 months (13 weeks); fixed: true; labelExcerpt: The recommended dose is 150 mg of Depo-Provera CI every 3 months (13 weeks) administered by deep, intramuscular (IM) injection in the gluteal or deltoid muscle.

Pediatric dosing

  • prevention of pregnancy: dose: 150; unit: mg; route: IM; interval: every 3 months (13 weeks); fixed: true; labelExcerpt: The recommended dose is 150 mg of Depo-Provera CI every 3 months (13 weeks) administered by deep intramuscular (IM) injection using strict aseptic technique in the gluteal or deltoid muscle, rotating the sites with every injection.

Renal adjustment

  • Consult pharmacy/current label

Hepatic adjustment

  • Use is contraindicated in significant liver disease.

Contraindications

  • Active thrombophlebitis
  • History of thromboembolic disorders
  • Known or suspected breast malignancy
  • Significant liver disease
  • Undiagnosed vaginal bleeding

Clinical pearls

  • Associated with significant loss of bone mineral density; use longer than 2 years is not recommended unless other options are inadequate.
  • Must be administered via deep IM injection in gluteal or deltoid muscle; rotate sites.
  • Ensure patient is not pregnant before first injection; administer only during first 5 days of menses or first 5 days post-partum (or after 6th week post-partum if breastfeeding).
  • Monitor for symptoms of meningioma, ectopic pregnancy, and thromboembolic disorders.

Source and review

  • DailyMed label (medroxyprogesterone acetate, Depo-Provera), Set ID 199cf13e-0859-4a73-9b45-e700d0cd1049, effective 2026-08-25. Last reviewed: 2026-11-11